Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice
暂无分享,去创建一个
K. Nakao | A. Fukamizu | K. Tanimoto | D. Garbers | I. Kishimoto | Yoshihiko Saito | M. Nakanishi | M. Harada | K. Kuwahara | Y. Adachi | S. Yasuno | Y. Nakagawa | R. Kawakami | N. Takahashi | S. Usami | Yuhao Li
[1] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[2] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[3] Michael D. Schneider,et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.
[4] K. Nakao,et al. Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes , 2003, Circulation.
[5] K. Nakao,et al. Guanylyl Cyclase-A Inhibits Angiotensin II Type 1A Receptor-Mediated Cardiac Remodeling, an Endogenous Protective Mechanism in the Heart , 2002, Circulation.
[6] Alan S Maisel,et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.
[7] A. Gavazzi,et al. [Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[8] E. Hartter,et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.
[9] M. Kinoshita,et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. , 2001, Journal of the American College of Cardiology.
[10] H. Dargie,et al. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.
[11] J. Knowles,et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.
[12] T. Nakayama,et al. Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. , 2000, Circulation research.
[13] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[14] Y. Yazaki,et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. , 1999, Circulation.
[15] H. S. Kim,et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] D. Garbers,et al. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. T. Lie,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.
[18] D. Garbers,et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.
[19] Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction , 1994, The Lancet.
[20] K. Nakao,et al. Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction , 1993, Circulation.
[21] Michihisa Jougasaki,et al. Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.
[22] K. Nakao,et al. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.
[23] M. Pfeffer,et al. Myocardial Infarct Size and Ventricular Function in Rats , 1979, Circulation research.
[24] A. Wear. CIRCULATION , 1964, The Lancet.
[25] I. Piña. Clinical trials report , 2004 .
[26] 和泉 武彦. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury , 2003 .
[27] O. Smithies,et al. Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy. , 2002, American journal of physiology. Heart and circulatory physiology.
[28] T. Horio,et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. , 2000, Hypertension.
[29] Orton,et al. INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .